Drug resistance remains the central unsolved problem in multiple myeloma management, and understanding why some plasma cell tumors persist despite cutting-edge immunotherapies may require looking beyond genetics into metabolism itself. A comprehensive review in Critical Reviews in Oncology/Hematology argues that metabolic reprogramming in multiple myeloma is not a passive byproduct of malignancy but an active, coordinated adaptive system that renders tumors functionally invisible to current treatment strategies.
The review systematically maps how malignant plasma cells rewire five interconnected metabolic axes — glucose, lipid, amino acid, nucleotide, and trace element metabolism, specifically iron and copper — to sustain proliferation and evade immune surveillance. Each pathway is shown to interact with the bone marrow microenvironment and with therapeutic selection pressure, creating a dynamic network that evolves in response to proteasome inhibitors and immunotherapies. Notably, the authors identify the gut microbiota as a distal metabolic regulator, with microbial metabolites influencing myeloma progression through systemic signaling. The review further argues that these metabolic states encode clinically meaningful information currently absent from standard staging systems like the International Staging System.
This synthesis arrives at a moment when the myeloma field is grappling with a paradox: survival outcomes have improved substantially, yet cure remains elusive for most patients. The metabolic lens offers a genuinely complementary explanatory framework, particularly for understanding why genetically similar tumors diverge in drug response. However, the central limitation of this work is its nature as a narrative review — it synthesizes existing mechanistic and preclinical literature without new clinical validation. Most metabolic vulnerability data remain derived from in vitro models or small cohort studies, and translating specific metabolic targets into approved therapies has proven historically difficult in oncology. The practical value here lies in the framework it proposes: metabolic profiling as a biomarker and risk stratification tool, not yet as a standalone treatment guide. For the field to advance, prospective trials testing metabolic inhibitors alongside standard regimens will be essential.